Biocept announces pricing of $5.0 million underwritten public offering

San diego--(business wire)--biocept, inc. (nasdaq: bioc) (“biocept” or the “company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share (or pre-funded warrant in lieu thereof) and an accompanying warrant t.
BIOC Ratings Summary
BIOC Quant Ranking